Mutant KRAS promotes epithelial–mesenchymal transition (EMT), a process characterized by the loss of epithelial cellular adhesion and increased cellular motility, and suppresses immune surveillance to allow circulating tumor cells to colonize distant sites. Here, KRAS is linked to neoplasm.